755 results on '"Gastl, G"'
Search Results
2. Hämatologie, Onkologie und Gerinnungsstörungen
3. Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)
4. Phytopharmaka in der Onkologie
5. Methoden zum Nachweis und Monitoring einer HIV Infektion
6. Immuntherapie des metastasierten Nierenzellkarzinoms mit rekombinantem Interferon-γ
7. Strategies for Optimizing Cytokine Treatment of Malignancies: Determination of Interferon Sensitivity in Chronic Myelocytic Leukemia
8. Anti-Proliferative and Anti-Tumor Effect of α-Interferon in Renal Cell Carcinoma: Correlation with the Expression of a Kidney Associated Differentiation Glycoprotein
9. Sekundäre Immundefekte
10. Primäre Immundefekte
11. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories
12. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients
13. Acute Effects of Recombinant IFN-γ on White Blood Cell Counts and Lymphocyte Subsets in the Peripheral Blood of Cancer Patients
14. Heterogenous Progenitor Sensitivity to Various Cytokines in Patients with Myeloproliferative Disorders; Correlation of In Vitro Interferon-α Sensitivity with the Clinical Responsiveness to Recombinant Interferon-α
15. Präklinische Testung und Verlaufsparameter bei Interferon-Therapie
16. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
17. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients
18. Bone marrow may be the preferable graft source in recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors
19. Preoperative Chemotherapy with Cisplatin and Docetaxel Followed by Surgery and Clip-Oriented Postoperative Chemoradiation in Patients with Localized Gastric or Gastroesophageal Junction Adenocarcinoma: Results from a Phase II Feasibility Study
20. TROP2 expression as prognostic marker for gastric carcinoma
21. Alemtuzumab in chronic lymphocytic leukaemia, other lymphoproliferative disease and autoimmune disorders
22. Proceedings of the Annual Meeting of the Austrian Society of Haematology and Oncology
23. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance
24. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
25. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution
26. Aberrant Tetranectin Expression in Human Breast Carcinomas as a Predictor of Survival
27. GRP78 a mediator of intrinsic and extrinsic tumor resistance: SW04.S17–50
28. Evaluation of optimal survival of primitive progenitor cells (LTC-IC) from PBPC apheresis products after overnight storage
29. Bone marrow may be the preferable graft source for transplant recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors: P522
30. Progression-free survival of recipients with HLA-C KIR ligand group 2 homozygosity is impaired following peripheral blood stem cell transplantation (PBSCT) but not after bone marrow transplantation (BMT): V703
31. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient Cytotoxic T Lymphocytes combined with a Dendritic Cell Vaccine: V328
32. Significantly higher and more rapid cytogenetic and molecular responses can be achieved in pre-treated chronic phase CML patients with high doses of Imatinib as induction therapy (800 mg/day, 6 months) - final results of a Phase III CELSG CML11 “ISTAHIT” TRIAL: V278
33. Functional analysis of the matrixmetalloproteinase-11 in tumor growth, angiogenesis and metastasis: B5.35
34. Functional analysis of Epithelial cell adhesion molecule (EpCAM) in breast cancer cell lines: B2.64
35. Approaching personalized cancer medicine
36. High Dose Imatinib (800mg/day) improves Cytogenetic and Molecular Remissions in pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase; Results from the CELSG CML 11 “ISTAHIT” Phase III Study: V57
37. A low or high body mass index is not predictive for outcome following allogeneic haematopoietic stem cell transplantation: R1247
38. Effective Bortezomib-Based Therapy for IgM Myeloma in 2 Patients with Unique Cytogenetic Features: A320
39. Free Light Chain (by rFLC) Monitoring Reveals Early Relapse After HSCT: A326
40. Local expression of cytokines in rat bladder carcinoma tissue after intravesical treatment withNocardia rubra cell wall skeleton and bacille-Calmette-Guerin
41. T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation
42. IgM myeloma: more on a rare entity
43. Naturally occurring CD4+ CD25+ regulatory T cells modulate the haematopoietic potential of human stem cells in vitro
44. Palliative therapy of giant basal cell carcinoma with the monoclonal anti-epidermal growth factor receptor antibody cetuximab
45. Current and future strategies to block tumor angiogenesis, invasion, and metastasis
46. Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study
47. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients
48. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation
49. Fludarabine and high-dose cytosine arabinoside followed by allogeneic haematopoietic stem cell transplantation in patients with high-risk leukaemia
50. Dexverapamil to overcome epirubicin resistance in advanced breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.